Ipsen provides update on legacy of Henri Beaufour

Core Viewpoint - Ipsen is undergoing a transfer of shares from Beech Tree to the Alasol Foundation, following the wishes of the late Mr. Henri Beaufour, a board member and representative of the founding family [1][2]. Group 1: Share Transfer Details - Beech Tree is the holding company that owns Mr. Beaufour's stake in Ipsen [2]. - The Alasol Foundation, created by Mr. Beaufour, focuses on promoting education and vocational training for disadvantaged children and young adults [2]. - The share transfer is expected to occur in early 2026, pending regulatory approvals [1]. Group 2: Company Overview - Ipsen is a global biopharmaceutical company specializing in transformative medicines across three therapeutic areas: Oncology, Rare Disease, and Neuroscience [3]. - The company has nearly 100 years of development experience and operates global hubs in the U.S., France, and the U.K., with teams in over 40 countries [3]. - Ipsen's medicines reach patients in more than 100 countries, supported by both internal and external innovation [3]. Group 3: Stock Information - Ipsen is listed on Euronext Paris under the ticker IPN and has a Sponsored Level I American Depositary Receipt program in the U.S. under the ticker IPSEY [4].